3 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Untitled document
    3
    1. karim2001khoury 19 Feb 2026
      A deregulated HOX gene axis confers an epigenetic vulnerability in KRAS-mutant lung cancers

      [Paper-level Aggregated] PMCID: PMC10805385

      Evidence Type(s): Oncogenic, Predictive

      Justification: Oncogenic: The text indicates that HOXC10 is overexpressed in KRAS-mutant tumors, specifically mentioning the KRAS G12C variant, which is known to be associated with oncogenic activity in cancer. Predictive: The mention of robust HOXC10 expression in a patient-derived xenograft model with the KRAS G12C variant suggests that HOXC10 expression may predict response to treatment with MEK/BET inhibitors, indicating its potential as a predictive biomarker.

      Gene→Variant (gene-first): KRAS(3845):G12C TP53(7157):G245V

      Genes: KRAS(3845) TP53(7157)

      Variants: G12C G245V

      CIViC paper-level aggregated PMC10805385
    2. karim2001khoury 19 Feb 2026
      HOXC10 is overexpressed in 51% of primary KRAS-mutant tumors (Figure 3A; TCGA, >= 2SD over expression in normal lung), consistent with observations in cell lines (Figure 2B). By analyzing KRAS-mutant tumor/normal matched

      [Paragraph-level] PMCID: PMC10805385 Section: RESULTS PassageIndex: 17

      Evidence Type(s): Oncogenic, Predictive

      Justification: Oncogenic: The passage discusses the overexpression of HOXC10 in KRAS-mutant tumors, specifically mentioning the genotype KRAS G12C/TP53 G245V, indicating that these somatic variants contribute to tumor development or progression. Predictive: The passage mentions the efficacy of combined MEK/BET inhibitors causing tumor regression in KRAS-mutant patient-derived xenograft models, suggesting a correlation between the variants and response to therapy.

      Gene→Variant (gene-first): 3845:G12C 7157:G245V

      Genes: 3845 7157

      Variants: G12C G245V

      CIViC paragraph-level PMC10805385 Oncogenic Predictive
    3. karim2001khoury 19 Feb 2026
      HOXC10 is overexpressed in 51% of primary KRAS-mutant tumors (Figure 3A; TCGA, >= 2SD over expression in normal lung), consistent with observations in cell lines (Figure 2B). By analyzing KRAS-mutant tumor/normal matched

      [Paragraph-level] PMCID: PMC10805385 Section: RESULTS PassageIndex: 17

      Evidence Type(s): Oncogenic, Predictive

      Justification: Oncogenic: The passage discusses the overexpression of HOXC10 in KRAS-mutant tumors, specifically mentioning the genotype KRAS G12C/TP53 G245V, indicating that these somatic variants contribute to tumor development or progression. Predictive: The passage mentions the efficacy of combined MEK/BET inhibitors causing tumor regression in KRAS-mutant patient-derived xenograft models, suggesting a correlation between the variants and response to therapy.

      Gene→Variant (gene-first): 3845:G12C 7157:G245V

      Genes: 3845 7157

      Variants: G12C G245V

      CIViC paragraph-level PMC10805385 Oncogenic Predictive
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC10805385/pdf/nihms-1588552.pdf